Mode
Text Size
Log in / Sign up

Meta-analysis shows percutaneous irreversible electroporation plus immunotherapy improves outcomes in locally advanced pancreatic cancerAdding immunotherapy to ablation therapy extends life for pancreatic cancer patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider percutaneous irreversible electroporation plus immunotherapy for locally advanced pancreatic cancer based on this meta-analysis.

This systematic review and meta-analysis examined the efficacy and safety of percutaneous irreversible electroporation combined with immunotherapy compared to irreversible electroporation alone. The analysis included data from 310 patients with locally advanced pancreatic cancer. The primary outcomes assessed were progression-free survival, overall survival, CA 19-9 levels, and adverse events.

The combined intervention significantly prolonged progression-free survival with a hazard ratio of 0.56; 95%CI=0.39 - 0.80; p<0.01; I2=10%. Overall survival was also greater with a hazard ratio of 0.52; 95%CI=0.37 - 0.73; p<0.01; I2=0%. Additionally, CA 19-9 levels were significantly lower with a mean difference of -70.18U/L; 95%CI=-121.07 - -19.29; p<0.01; I2=98%.

Regarding safety, there was no significant difference in adverse events for nausea and vomiting with an odds ratio of 1.58; 95%CI=0.71 - 3.49; p=0.26; I2=0%. Similarly, no significant difference was found for gastroparesis with an odds ratio of 0.88; 95%CI=0.23 - 3.40; p=0.85; I2=0%. Serious adverse events, discontinuations, and the specific setting were not reported. Funding or conflicts of interest were also not reported.

Imagine a patient facing a very tough diagnosis. Locally advanced pancreatic cancer is often hard to treat. Many options are limited. Doctors need new ways to help.

A new analysis offers hope. It looks at a specific combination of treatments. This mix might change the outlook for patients.

The Problem With Current Treatments

Pancreatic cancer is a serious disease. It grows fast and spreads easily. Many people have surgery. But not everyone can have it. Some tumors are too big or in the wrong spot.

Doctors often use other methods. One is irreversible electroporation. This uses electricity to create tiny holes in cancer cells. It stops them from growing. But using it alone has limits.

The immune system is our body's defense. It fights off invaders. Sometimes it works well against cancer. But often it needs a boost. Current treatments do not always give that boost.

A New Twist In The Approach

But here is the twist. Adding immune therapy changes the game. The new research shows a powerful combination. It pairs the electrical treatment with drugs that wake up the immune system.

Think of the immune system as a security guard. The electrical treatment removes the bad guys. The drugs make the guard stronger. Together they do more than either could alone.

The electrical method creates small pores in cell walls. This is like opening a door. It lets drugs get inside the tumor. It also exposes hidden parts of the cancer.

The immune system sees these parts. It recognizes them as threats. The drugs help the immune system attack. This creates a stronger defense against the disease.

Four studies were included in this review. They looked at 310 patients total. The results were clear and positive.

Patients getting both treatments lived longer. Their time without cancer growth was much better. The numbers show a significant improvement in survival rates.

Tumor markers also dropped lower. CA 19-9 is a common marker for this cancer. Lower levels mean the treatment is working well.

This doesn't mean this treatment is available yet.

Safety And Side Effects

Safety is a major concern for patients. Doctors worry about extra side effects. The review checked for nausea and vomiting. It also checked for gastroparesis.

The results were reassuring. Side effects did not increase with the combination. Patients did not suffer more than those getting the electrical treatment alone. This is a huge plus.

What This Means For Patients

This news is important for many families. It gives doctors a new tool. It offers hope for those who need it. Patients can talk to their doctors about options.

It is not a cure for everyone. But it is a strong step forward. More data will come as research continues.

More trials are needed. Larger groups of patients will be studied. This will confirm the findings. Regulatory bodies must review the data.

Approval takes time. It ensures safety for everyone. The goal is to bring this to more people. Research moves slowly but steadily.

The future looks brighter. New combinations are being tested. Science continues to find better ways to fight cancer. Hope remains for patients everywhere.

Study Details

Study typeMeta analysis
Sample sizen = 310
EvidenceLevel 1
PublishedJan 2026
View Original Abstract ↓
OBJECTIVE: The aim of this meta-analysis was to determine the efficacy and safety of percutaneous irreversible electroporation combined with immunotherapy compared with irreversible electroporation alone in patients with locally advanced pancreatic cancer. METHODS: We systematically searched Embase, Cochrane Central Register of Controlled Trials, and PubMed/Medline for relevant studies. The outcomes of interest were progression-free survival, overall survival, carbohydrate antigen 19-9 (CA 19-9) levels, and adverse events. Progression-free survival and overall survival were assessed using pooled hazard ratios (HR), odds ratios (OR) were used for adverse events, and mean differences (MD) for CA 19-9. RESULTS: Four studies involving 310 patients were included in the pooled analysis. Irreversible electroporation combined with immunotherapy significantly prolonged progression-free survival compared with irreversible electroporation alone (hazard ratio [HR], 0.56; 95%CI=0.39 - 0.80; p<0.01; I2=10%). Additionally, patients who received irreversible electroporation plus immunotherapy achieved a greater overall survival compared with irreversible electroporation alone (HR=0.52; 95%CI=0.37 - 0.73; p<0.01; I2=0%). The pooled results for CA 19-9 showed significantly lower levels in patients receiving irreversible electroporation and immunotherapy compared with those receiving irreversible electroporation alone (MD: -70.18U/L; 95%CI=-121.07 - -19.29; p<0.01; I2=98%). No significant difference in the occurrence of adverse events such as nausea and vomiting (OR=1.58; 95%CI=0.71 - 3.49; p=0.26; I2=0%) and gastroparesis (OR=0.88; 95%CI=0.23 - 3.40; p=0.85; I2=0%) was not observed between the groups. CONCLUSION: Combined therapy using percutaneous irreversible electroporation and systemic immunotherapy offers a safe and effective treatment approach for locally advanced pancreatic cancer, with irreversible electroporation potentially enhancing the efficacy of systemic immunotherapy in combined applications. PROSPERO DATABASE REGISTRATION: ID CRD42024562216.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.